This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tron, V. A. Articles by Reed, J. C. Search for Related Content PubMed PubMed Citation Articles by Tron, V. A. Articles by Reed, J. C.

American Journal of Pathology, Vol 146, 643-650, Copyright © 1995 by American Society for Investigative Pathology

REGULAR ARTICLES

Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma

VA Tron, S Krajewski, H Klein-Parker, G Li, VC Ho and JC Reed
Department of Pathology, Vancouver Hospital and Health Sciences Centre, BC.

Cutaneous melanoma is becoming increasingly common. Genetic and environmental factors are thought to play a role in its pathogenesis. We have previously shown that normal human melanocytes strongly express the oncoprotein, Bcl-2. To determine the role of Bcl-2 in melanocytic tumors, we studied human benign nevi and melanomas for expression of Bcl-2 protein using immunohistochemistry. Our results show that benign melanocytes from 3 of 4 normal skin biopsies and 5 of 7 common acquired nevi strongly express Bcl-2. Conversely, only 3 of 23 primary cutaneous melanomas and 3 of 9 metastatic melanomas showed strong staining in comparison with melanocytes from normal skin and common acquired nevi (chi 2, P = 0.0021). Interestingly, 0 of 6 dysplastic nevi, a precursor of melanoma, demonstrated strong staining as compared with melanocytes and nevi (8 of 11; chi 2, P = 0.02), but similar expression to that of melanoma (6 of 32; chi 2, P = 0.6). We conclude that Bcl-2 expression decreases in malignant melanoma and suggest that this may be related to the autonomous growth characteristics of malignant melanoma.

This article has been cited by other articles:

				J.-Z. Qin, H. Xin, L. A. Sitailo, M. F. Denning, and B. J. Nickoloff Enhanced Killing of Melanoma Cells by Simultaneously Targeting Mcl-1 and NOXA Cancer Res., October 1, 2006; 66(19): 9636 - 9645. [Abstract] [Full Text] [PDF]

				L. Chin, L. A. Garraway, and D. E. Fisher Malignant melanoma: genetics and therapeutics in the genomic era. Genes & Dev., August 15, 2006; 20(16): 2149 - 2182. [Abstract] [Full Text] [PDF]

				M R Hussein Analysis of Bcl-2 protein expression in choroidal melanomas J. Clin. Pathol., May 1, 2005; 58(5): 486 - 489. [Abstract] [Full Text] [PDF]

				L. Benimetskaya, J. C. Lai, A. Khvorova, S. Wu, E. Hua, P. Miller, L.-M. Zhang, and C. A. Stein Relative Bcl-2 Independence of Drug-Induced Cytotoxicity and Resistance in 518A2 Melanoma Cells Clin. Cancer Res., December 15, 2004; 10(24): 8371 - 8379. [Abstract] [Full Text] [PDF]

				K. A. DiVito, A. J. Berger, R. L. Camp, M. Dolled-Filhart, D. L. Rimm, and H. M. Kluger Automated Quantitative Analysis of Tissue Microarrays Reveals an Association between High Bcl-2 Expression and Improved Outcome in Melanoma Cancer Res., December 1, 2004; 64(23): 8773 - 8777. [Abstract] [Full Text] [PDF]

				E. Petitclerc, S. Stromblad, T. L. von Schalscha, F. Mitjans, J. Piulats, A. M. P. Montgomery, D. A. Cheresh, and P. C. Brooks Integrin {{alpha}}V{beta}3 Promotes M21 Melanoma Growth in Human Skin by Regulating Tumor Cell Survival Cancer Res., June 1, 1999; 59(11): 2724 - 2730. [Abstract] [Full Text] [PDF]

				J S Chana, G D Wilson, I A Cree, R A Alexander, N Myatt, M Neale, A J E Foss, and J L Hungerford c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma Br. J. Ophthalmol., January 1, 1999; 83(1): 110 - 114. [Abstract] [Full Text]